Prevalence of thrombophilia and catheter-related thrombosis in cystic fibrosis

Venous thrombosis in children and young adults is frequently associated with predisposing conditions and with an indwelling catheter or totally implantable venous access device (TIVAD). These systems are commonly used for the delivery of antibiotic therapy in patients with cystic fibrosis (CF). We r...

Full description

Saved in:
Bibliographic Details
Published inPediatric pulmonology Vol. 39; no. 2; pp. 156 - 161
Main Authors Barker, Michael, Thoenes, Daniel, Döhmen, Hiltrud, Friedrichs, Frank, Pfannenstiel, Claus, Heimann, Gerhard
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.02.2005
Wiley-Liss
Subjects
Online AccessGet full text
ISSN8755-6863
1099-0496
DOI10.1002/ppul.20158

Cover

More Information
Summary:Venous thrombosis in children and young adults is frequently associated with predisposing conditions and with an indwelling catheter or totally implantable venous access device (TIVAD). These systems are commonly used for the delivery of antibiotic therapy in patients with cystic fibrosis (CF). We reviewed our CF center's history of catheter‐related events over 13 years and prospectively investigated the presence of risk factors for thrombosis in 66 children and adults with CF (age, 3–38 years; 32 females). Five thrombotic events had occurred in 4 patients, 2 of whom carried the factor V Leiden mutation. Five asymptomatic patients were diagnosed with heterozygous mutations of the factor V or prothrombin gene. Functional activity of protein C was decreased in 13 subjects, with a correlation to impaired liver function. Protein S activity was abnormal in 20 patients and was related to CF genotype. Anti‐phospholipid antibodies (APA) were present in 6 asymptomatic patients. A reinvestigation after 3 years confirmed protein S deficiency in 12 of 14 patients, while most abnormalities for protein C or APA were inconsistent. In conclusion, a thrombophilic state was detected in 53% of patients, and 2 out of 4 subjects with TIVAD‐related thrombosis carried a genetic defect. It may thus be helpful to include a hemostatic evaluation in the clinical decision process for or against TIVAD insertion in eligible CF patients. Pediatr Pulmonol. 2005;39:156–161. © 2005 Wiley‐Liss, Inc.
Bibliography:ArticleID:PPUL20158
istex:C797B49A39A89909FBCBC653A7E524489C5CB182
ark:/67375/WNG-J6G1FNBZ-9
Presented in part at the European Respiratory Society Annual Congress, 2002, Stockholm, Sweden.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.20158